Mitsubishi Tanabe Obtains Kremezin Domestic Marketing Rights From Kureha
This article was originally published in PharmAsia News
Executive Summary
Japanese drug maker Kureha Oct. 5 granted Mitsubishi Tanabe Pharma Japanese marketing rights to chronic renal failure drug Kremezin (AST-120)